CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-19 | Goldan Keith A. Chief Financial Officer | Purchase | +3,000 | 93,746 | ||
| 2025-05-19 | Huber Martin H. Jr. Director | Purchase | +5,000 | $8.99 | $45K | 79,000 |
| 2025-05-19 | Katkin Keith Director | Purchase | +10,000 | $9.11 | $91K | 100,000 |
| 2025-05-16 | Botwood Nicholas A.J. Head of R&D, CMO | Purchase | +11,765 | $9.00 | $106K | 35,165 |
| 2024-06-14 | Goldan Keith A. Chief Financial Officer | Purchase | +1,250 | $20.03 | $25K | 52,623 |
Page 1 of 1 · 5 trades